Bladder cancer tumor marker, antibody and use thereof
US9073995B2 · kind B2 · utility
0Cited by
2References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 12, 2011 |
| Grant date | Jul 7, 2015 |
| Priority date | — |
| Expiry date | Jan 8, 2032 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2440/38
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided in the present invention are an aberrantly glycosylated integrin, AG-α3β1, and use thereof as a bladder cancer marker. Also provided in the present invention are a hybridoma cell generating an anti-AG-α3β1 monoclonal antibody, a monoclonal antibody BCMab1 secreted by the same, and use of BCMab1 in the preparation of a medicament for the treatment of bladder cancer. Also provided in the present invention is use of inhibitors of GAL3ST2 and N-acetylgalactosaminyltransferase 1 in the preparation of a medicament for the treatment of bladder cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.